Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373816 | 1.00 | TLR8 (1.00) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL5765916 | 0.99 | TLR8 (0.97) | TLR8TLR7 | |
| SCHEMBL1528149 | 0.92 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1527936 | 0.91 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1528137 | 0.88 | TLR8 (1.00) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL5767005 | 0.87 | TLR8 (0.97) | TLR8TLR7 | |
| SCHEMBL1527831 | 0.86 | TLR8 (0.75) | TLR8TLR7 | |
| SCHEMBL5767961 | 0.84 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL24052764 | 0.84 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL5767746 | 0.84 | TLR8 (0.70) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 860 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599557-B2 | Liposomal sustained-release compositions containing a therapeutic drug and use thereof | TLC BIOPHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4683654-A1 | SIRP VARIANTS AND USES THEREOF | Li, Wangzhi (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260014092-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION | AGS THERAPEUTICS SAS (FR) | 2026-01-15 | — | — | US | claimed |
| US-12514936-B2 | Composition comprising catalase, preparation method and use thereof and method for killing tumor cells | BEIJING PHARBERS GENESIS PHARM-TECH CO., LTD. (CN) | 2026-01-06 | — | — | US | claimed |
| EP-4637712-A1 | NANOPARTICULATE FORMULATION | Newimmune II, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | claimed |
| EP-4559479-A2 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250049915-A2 | NANOPARTICULATE FORMULATION | NEWIMMUNE II, LLC (US) | 2025-02-13 | — | — | US | claimed |
| EP-4493166-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | Baylor College of Medicine (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119278032-A | Enhancement of persistent antitumor immunity by multifactorial immunomodulation | 贝勒医学院 | 2025-01-07 | — | — | CN | claimed |
| WO-2002102377-A1 | IMMUNE RESPONSE MODIFIERS FOR THE TREATMENT OF PERIODONTAL DISEASE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-12-27 | — | — | WO | claimed |
| JP-2002524392-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2002-06-13 | — | — | US | claimed |
| US-20020058674-A1 | Systems and methods for treating a mucosal surface | 3M INNOVATIVE PROPERTIES COMPANY | 2002-05-16 | — | — | US | claimed |
| US-20020016332-A1 | Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-07 | — | — | US | claimed |
| WO-2001097795-A2 | SYSTEMS AND METHODS FOR TREATING A MUCOSAL SURFACE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001074343-A2 | METHOD FOR THE TREATMENT OF DERMAL LESIONS CAUSED BY ENVENOMATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | claimed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | claimed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885 |
| US-20250049915-A2 | NANOPARTICULATE FORMULATION | MYD88, CD47, TLR9 | TLR8 12/4885TLR7 8/4885 |
| US-20020058674-A1 | Systems and methods for treating a mucosal surface | INMT, ICOS, HRH2 | TLR8 31/4885TLR7 4/4885 |
| US-20260014092-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION | TLR9, TLR1, TLR2 | TLR8 7/4885TLR7 9/4885 |
| US-12599557-B2 | Liposomal sustained-release compositions containing a therapeutic drug and use thereof | SGMS2, TLR7, SMPD1 | TLR8 100/4885TLR7 2/4885 |
| US-20020016332-A1 | Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers | STING1, HRH4, ICOS | TLR8 89/4885TLR7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.